Top

Published in:

Open Access 01-12-2015 | Research article

Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?

Authors: Paolo Fuzio, Anna Napoli, Anna Ciampolillo, Serafina Lattarulo, Angela Pezzolla, Nicoletta Nuzziello, Sabino Liuni, Francesco Giorgino, Eugenio Maiorano, Elda Perlino

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Clusterin (CLU) is a ubiquitous multifunctional factor involved in neoplastic transformation. The CLU transcript variants and protein forms play a crucial role in balancing cells proliferation and death.

Methods

We investigated the regulation of CLU transcript variants expression in an in vivo model system consisting of both neoplastic tissues and fine needle aspiration biopsy (FNAB) samples isolated from patients undergoing thyroidectomy.

Results

The immunohistochemical analyses showed an overall CLU up-regulation in papillary carcinoma. A specific CLU2 transcript variant increase was registered using qPCR in papillary carcinomas while CLU1 decreased. In addition, the analysis of CLU transcripts expression level showed an increase of the CLU2 transcript in the TIR 3 patients with histologically confirmed thyroid cancer.

Conclusions

Our results suggest the existence of a specific alteration of CLU2:CLU1 ratio towards CLU2, thus providing the first circumstantial evidence for the potential use of CLU transcript variants as effective biomarkers for a more accurate assessment of the so called “indeterminate” thyroid nodules.

Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, editors. Endocrine tumors. Cambridge: Blackwell Scientific; 1993. p. 278–333.

Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545–76.PubMed

DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662–9.CrossRefPubMed

Møller MB. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan Med Bull. 2003;50:118–38.PubMed

Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 1995;27:633–45.CrossRefPubMed

Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13:12–9.CrossRefPubMed

Trougakos IP, Lourda M, Agiostratidou G, Kletsas D, Gonos ES. Differential effects of clusterin/apolipoprotein J on cellular growth and survival. Free Radic Biol Med. 2005;38:436–49.CrossRefPubMed

Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, et al. Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB activity in prostate cancer cells. Mol Cancer Res. 2010;8:119–30.CrossRefPubMedPubMedCentral

Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 2004;64:6174–82.CrossRefPubMed

10.

Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ. Clusterin overexpression in both malignant and non-malignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer. 2004;91:1842–50.CrossRefPubMedPubMedCentral

11.

Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdörfer M. Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathway. PLoS One. 2013;8:e75303.CrossRefPubMedPubMedCentral

12.

Ling IF, Bhongsatiern J, Simpson JF, Fardo DW, Estus S. Genetics of clusterin isoform expression and Alzheimer’s disease risk. PLoS One. 2012;7:e33923.CrossRefPubMedPubMedCentral

13.

Moretti RM, Marelli MM, Mai S, Cariboni A, Scaltriti M, Bettuzzi S, et al. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res. 2007;67:10325–33.CrossRefPubMed

14.

Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393–9.CrossRefPubMedPubMedCentral

15.

Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int. 2005;96:895–9.CrossRefPubMed

16.

Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;23:2298–304.CrossRefPubMed

17.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223–32.PubMed

18.

Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002;8:3276–84.PubMed

19.

Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, et al. Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting Clusterin improves response to paclitaxel. J Exp Clin Cancer Res. 2011;113:1–14.

20.

Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398–404.PubMed

21.

Fuzio P, Valletti A, Napoli A, Napoli G, Cormio G, Selvaggi L, et al. Regulation of the expression of CLU isoforms in endometrial proliferative diseases. Int J Oncol. 2013;42:1929–44.PubMed

22.

Seol MB, Bong JJ, Baik M. Expression profiles of apoptosis genes in mammary epithelial cells. Mol Cell. 2005;20:97–104.

23.

Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs. 2006;15:507–17.CrossRefPubMed

24.

Lemansky P, Brix K, Herzog V. Subcellular distribution, secretion, and post-translational modifications of clusterin in thyrocytes. Exp Cell Res. 1999;251:147–55.CrossRefPubMed

25.

Wegrowski Y, Perreau C, Martiny L, Haye B, Maquart F, Bellon G. Transforming growth factor β-1 Up-regulates clusterin synthesis in thyroid epithelial cells. Exp Cell Res. 1999;247:475–83.CrossRefPubMed

26.

Kashat L, So A, Masui O, Wang XS, Cao J, Meng X, et al. Secretome based identification and characterization of potential biomarkers in thyroid cancer. J Proteome Res. 2010;9:5757–69.CrossRefPubMed

27.

Castrignanò T, D’Antonio M, Anselmo A, Carrabino D, D’Onorio De Meo A, D'Erchia AM, et al. ASPicDB: a database resource for alternative splicing analysis. Bioinformatics. 2008;24:1300–4.CrossRefPubMed

28.

Martelli PL, D’Antonio M, Bonizzoni P, Castrignanò T, D’Erchia AM, D’Onorio De Meo P, et al. ASPicDB: a database of annotated transcript and protein variants generated by alternative splicing. Nucleic Acids Res. 2011;39:D80–5.CrossRefPubMed

29.

Riva A, Pesole G. A unique, consistent identifier for alternatively spliced transcript variants. PLoS One. 2009;4:e7631.CrossRefPubMedPubMedCentral

30.

Schepeler T, Mansilla F, Christensen LL, Ørntoft TF, Andersen CL. Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. J Mol Signal. 2007;2:1–12.CrossRef

31.

Pucci S, Bettuzzi S. Chapter 3: The shifting balance between CLU forms during tumour progression. Adv Cancer Res. 2009;104:25–32.CrossRefPubMed

32.

Fadda G, Basolo F, Bondi A, Bussolati G, Crescenzi A, Nappi O, et al. Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica. 2010;102:405–8.PubMed

33.

Song HB, Jun HO, Kim JH, Yu YS, Kim KW, Min BH, et al. Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells. Oncol Rep. 2013;30:2713–8.PubMed

34.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010. p. 87–96.

35.

Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res. 2003;31:e73.CrossRefPubMedPubMedCentral

Title: Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?
Authors: Paolo Fuzio
Anna Napoli
Anna Ciampolillo
Serafina Lattarulo
Angela Pezzolla
Nicoletta Nuzziello
Sabino Liuni
Francesco Giorgino
Eugenio Maiorano
Elda Perlino
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1348-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Oxalate induces breast cancer

Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis

GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells

ACTN4 and the pathways associated with cell motility and adhesion contribute to the process of lung cancer metastasis to the brain

Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure

Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer